CA2463578A1 - Differentially expressed genes associated with obesity and type 2 diabetes - Google Patents

Differentially expressed genes associated with obesity and type 2 diabetes Download PDF

Info

Publication number
CA2463578A1
CA2463578A1 CA002463578A CA2463578A CA2463578A1 CA 2463578 A1 CA2463578 A1 CA 2463578A1 CA 002463578 A CA002463578 A CA 002463578A CA 2463578 A CA2463578 A CA 2463578A CA 2463578 A1 CA2463578 A1 CA 2463578A1
Authority
CA
Canada
Prior art keywords
agt
seq
nucleotide sequence
nucleic acid
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002463578A
Other languages
English (en)
French (fr)
Inventor
Greg Collier
Paul Zev Zimmet
Ken Walder
Janine Mcmillan
Andrea Michelle De Silva
Kelly Windmill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deakin University
International Diabetes Institute
Autogen Research Pty Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2463578A1 publication Critical patent/CA2463578A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Plant Pathology (AREA)
  • Child & Adolescent Psychology (AREA)
CA002463578A 2001-10-16 2002-10-16 Differentially expressed genes associated with obesity and type 2 diabetes Abandoned CA2463578A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33014901P 2001-10-16 2001-10-16
US60/330,149 2001-10-16
PCT/AU2002/001405 WO2003033513A1 (en) 2001-10-16 2002-10-16 Differentially expressed genes associated with obesity and type 2 diabetes

Publications (1)

Publication Number Publication Date
CA2463578A1 true CA2463578A1 (en) 2003-04-24

Family

ID=23288511

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002463578A Abandoned CA2463578A1 (en) 2001-10-16 2002-10-16 Differentially expressed genes associated with obesity and type 2 diabetes

Country Status (9)

Country Link
EP (1) EP1446414A4 (zh)
JP (1) JP2005510214A (zh)
KR (1) KR20040088019A (zh)
CN (1) CN1596264A (zh)
CA (1) CA2463578A1 (zh)
IL (1) IL161294A0 (zh)
MX (1) MXPA04003635A (zh)
WO (1) WO2003033513A1 (zh)
ZA (1) ZA200402859B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004063218A1 (en) * 2003-01-13 2004-07-29 Autogen Research Pty Ltd Obesity-related genes
DE10352510A1 (de) * 2003-11-07 2005-06-23 Forschungsinstitut Für Die Biologie Landwirtschaftlicher Nutztiere Verfahren zur Identifizierung von Wirkstoffen zur Beeinflussung der Körpermasse und des Fettansatzes
CN1961074A (zh) * 2003-12-24 2007-05-09 三星电子株式会社 包含与ⅱ型糖尿病有关的单核苷酸多态性的多核苷酸、包含该多核苷酸的微阵列和诊断试剂盒以及使用它们分析多核苷酸的方法
US20080105961A1 (en) * 2004-03-16 2008-05-08 Gregory Royce Collier Ligands of the Molecule Fit (Agt-121) and their Pharmaceutical Use
US20100028326A1 (en) * 2004-12-07 2010-02-04 Ohio University Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on proteins differentially expressed in serum
CN114958875B (zh) * 2022-05-15 2023-08-18 赣南师范大学 柑橘黄龙病菌内参基因metG筛选和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2780405B1 (fr) * 1998-06-25 2001-12-28 Centre Nat Rech Scient Nouveaux recepteurs olfactifs et leurs utilisations
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides

Also Published As

Publication number Publication date
IL161294A0 (en) 2004-09-27
KR20040088019A (ko) 2004-10-15
WO2003033513A1 (en) 2003-04-24
ZA200402859B (en) 2005-01-24
EP1446414A1 (en) 2004-08-18
MXPA04003635A (es) 2004-07-30
JP2005510214A (ja) 2005-04-21
EP1446414A4 (en) 2005-11-23
CN1596264A (zh) 2005-03-16

Similar Documents

Publication Publication Date Title
US20080171702A1 (en) Novel gene and uses therefor
US20090143571A1 (en) Novel genes and their use in the modulation of obesity, diabetes and energy imbalance
US20070065915A1 (en) Nucleic acid expressed in the hypothalamus or muscle tissue in obese animals
CA2463578A1 (en) Differentially expressed genes associated with obesity and type 2 diabetes
US20040214188A1 (en) Gene and uses therefor
AU2002227795B2 (en) Nucleic acid expressed in the hypothalamus or muscle tissue in obese animals
US20050232918A1 (en) Differentially expressed genes associated with obesity and type 2 diabetes
WO2003016542A1 (en) Obesity related genes expressed at least in the hypothalamus
NZ530543A (en) A ligand of the protein "beacon"
AU2002332956A1 (en) Differentially expressed genes associated with obesity and type 2 diabetes
AU742651B2 (en) A novel gene and uses therefor
AU774097B2 (en) A novel regulatory molecule and genetic sequences encoding same
AU2002227795A1 (en) Nucleic acid expressed in the hypothalamus or muscle tissue in obese animals
AU2002308412A1 (en) A gene and uses therefor
CA2458849A1 (en) Obesity related genes expressed at least in the hypothalamus, liver or pancreas
NZ520101A (en) Treatment of obesity with a gene expressed in hypothalamus of obese animals
AU2002325644A1 (en) Obesity related genes expressed at least in the hypotalamus, liver or pancreas
AU3946900A (en) A ligand of the protein "beacon"

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued